Group 1 - The company is revising its articles of association, which requires approval from the shareholders' meeting and authorization for related registration procedures [1][2] - The revised governance systems have been approved by the company's board and supervisory board, with some requiring further approval from the shareholders' meeting [2][3] Group 2 - The company held an employee representative meeting on August 6, 2025, to elect Dong Wenkun as the employee representative director for the third board, whose term aligns with the new board [3][4] - Dong Wenkun has a background in pharmaceutical engineering and has held various positions within the company, including director of research and development [4][5] - As of the announcement date, Dong Wenkun does not directly hold company shares but has indirect holdings through a partnership, and he meets all legal qualifications for the position [5]
杭州安旭生物科技股份有限公司 关于选举第三届董事会职工 代表董事的公告